<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02021643</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-334-0115</org_study_id>
    <nct_id>NCT02021643</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Sofosbuvir Plus Ribavirin in Adults With Chronic HCV Infection</brief_title>
  <official_title>A Phase 3b, Multicenter, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin (± Pegylated Interferon) in Subjects With Chronic Genotype 1, 2, 3 and 6 HCV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to evaluate the efficacy, safety and tolerability of
      treatment with sofosbuvir (SOF)+ ribavirin (RBV), with or without Pegylated interferon alfa
      (Peg-IFNα-2a/ PEG)) in participants with chronic genotype (GT)-1, 2, 3, and 6 Hepatitis C
      virus (HCV) infection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 10, 2013</start_date>
  <completion_date type="Actual">November 3, 2016</completion_date>
  <primary_completion_date type="Actual">August 12, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)</measure>
    <time_frame>Posttreatment Week 12</time_frame>
    <description>SVR12 is defined as HCV RNA &lt; the lower limit of quantification (LLOQ; ie, &lt; 25 IU/mL) 12 weeks following the last dose of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</measure>
    <time_frame>Posttreatment Weeks 4 and 24</time_frame>
    <description>SVR4 and SVR24 are defined as HCV RNA &lt; LLOQ at 4 and 24 weeks following the last dose of study drug, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With On-Treatment Virologic Failure</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Viral breakthrough was defined as HCV RNA ≥ LLOQ after having previously had HCV RNA &lt; LLOQ while receiving treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Viral Relapse</measure>
    <time_frame>Up to Posttreatment Week 24</time_frame>
    <description>Viral relapse was defined as HCV RNA ≥ LLOQ during the post-treatment period having achieved HCV RNA &lt; LLOQ at end of treatment, confirmed with 2 consecutive values or last available post-treatment measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HCV RNA (log10 IU/mL)</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">687</enrollment>
  <condition>Chronic HCV Infection</condition>
  <arm_group>
    <arm_group_label>Sofosbuvir+RBV+PEG 12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 1 or 6 will receive sofosbuvir+RBV+Peg-IFNα-2a for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sofosbuvir+RBV 12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 1, 2 or 6 will receive sofosbuvir+RBV for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sofosbuvir+RBV 16 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 1, 6 will receive sofosbuvir+RBV for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sofosbuvir+RBV 24 Weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 1, 3, or 6 will receive sofosbuvir+RBV for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir</intervention_name>
    <description>Sofosbuvir 400 mg tablet administered orally once daily</description>
    <arm_group_label>Sofosbuvir+RBV+PEG 12 weeks</arm_group_label>
    <arm_group_label>Sofosbuvir+RBV 12 weeks</arm_group_label>
    <arm_group_label>Sofosbuvir+RBV 16 weeks</arm_group_label>
    <arm_group_label>Sofosbuvir+RBV 24 Weeks</arm_group_label>
    <other_name>Sovaldi®</other_name>
    <other_name>GS-7977</other_name>
    <other_name>PSI-7977</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RBV</intervention_name>
    <description>Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (&lt; 75kg = 1000 mg and ≥ 75 kg = 1200 mg)</description>
    <arm_group_label>Sofosbuvir+RBV+PEG 12 weeks</arm_group_label>
    <arm_group_label>Sofosbuvir+RBV 12 weeks</arm_group_label>
    <arm_group_label>Sofosbuvir+RBV 16 weeks</arm_group_label>
    <arm_group_label>Sofosbuvir+RBV 24 Weeks</arm_group_label>
    <other_name>Ribasphere®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG</intervention_name>
    <description>Pegylated interferon alfa-2a (Peg-IFNα-2a) 180 µg/0.5 mL pre-filled syringe administered subcutaneously once a week</description>
    <arm_group_label>Sofosbuvir+RBV+PEG 12 weeks</arm_group_label>
    <other_name>Pegasys®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Willing and able to provide written informed consent

          -  HCV RNA ≥ 10^4 IU/mL at screening

          -  HCV treatment-naive (HCV genotype 1, 2, 3 or 6), defined as no prior exposure to any
             interferon (IFN), RBV, or other approved or experimental HCV-specific direct-acting
             antiviral agent, or HCV treatment-experienced (HCV genotype 1, 2, 3, or 6 only) with
             medical records that include sufficient detail of prior treatment with IFN to allow
             for categorization of prior response as either IFN Intolerant, non-responder, or
             experiences viral breakthrough or relapse

          -  HCV infection documented by anti-HCV antibody test, genotyping test, or liver biopsy

        Key Exclusion Criteria:

          -  Current or prior history of any clinically-significant illness (other than HCV)

          -  Pregnant or nursing female or male with pregnant female partner

          -  Chronic liver disease of a non-HCV etiology

          -  Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fujian</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangdong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangxi</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hainan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hebei</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hubei</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hunan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jiangxi</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jilin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jin'an</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liaoyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sichuan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yunnan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zhejiang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sha Tin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Incheon</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ansan-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucheon-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chang-hua</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Keelung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
    <country>Vietnam</country>
  </location_countries>
  <results_reference>
    <citation>Lai CL, Wong VW, Yuen MF, Yang JC, Knox SJ, Mo H, Han LL, Brainard DM, Chan HL. Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong. Aliment Pharmacol Ther. 2016 Jan;43(1):96-101. doi: 10.1111/apt.13429. Epub 2015 Oct 26.</citation>
    <PMID>26503414</PMID>
  </results_reference>
  <results_reference>
    <citation>Ahn SH, Lim YS, Lee KS, Paik SW, Lee YJ, Jeong SH, Kim JH, Yoon SK, Yim HJ, Tak WY, Han SY, Yang JC, Mo H, Mathias A, Han L, Knox SJ, Brainard DM, Kim YJ, Byun KS, Kim YS, Heo J, Han KH. A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus. J Viral Hepat. 2016 May;23(5):358-65. doi: 10.1111/jvh.12499. Epub 2016 Feb 10.</citation>
    <PMID>26864153</PMID>
  </results_reference>
  <results_reference>
    <citation>Kao JH, Chien RN, Chang TT, Peng CY, Hu TH, Lo GH, Wang HY, Chen JJ, Yang JC, Knox SJ, Han L, Mo H, Mathias A, Brainard DM, Sheen IS, Hsu YC, Chu CJ, Chuang WL. A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection. Liver Int. 2016 Aug;36(8):1101-7. doi: 10.1111/liv.13082. Epub 2016 Mar 23.</citation>
    <PMID>26835876</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2013</study_first_submitted>
  <study_first_submitted_qc>December 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2013</study_first_posted>
  <results_first_submitted>August 11, 2017</results_first_submitted>
  <results_first_submitted_qc>August 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 20, 2018</results_first_posted>
  <last_update_submitted>August 11, 2017</last_update_submitted>
  <last_update_submitted_qc>August 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at 61 study sites in Asia. The first participant was screened on 10 December 2013. The last study visit occurred on 03 November 2016.</recruitment_details>
      <pre_assignment_details>815 participants were screened.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>SOF+PEG+RBV 12 Weeks</title>
          <description>Participants with genotype 1 or 6 received Sofosbuvir (Sovaldi®; SOF) 400 mg tablet once daily + Pegylated interferon alfa-2a (PEG) 180 µg/0.5 mL pre-filled syringe administered subcutaneously once a week + ribavirin (RBV) tablets (1000 or 1200 mg daily based on weight) for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>SOF+RBV 12 Weeks</title>
          <description>Participants with genotype 1, 2 or 6 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks</description>
        </group>
        <group group_id="P3">
          <title>SOF+RBV 16 Weeks</title>
          <description>Participants with genotype 1 or 6 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 16 weeks</description>
        </group>
        <group group_id="P4">
          <title>SOF+RBV 24 Weeks</title>
          <description>Participants with genotype 1, 3 or 6 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 24 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="156"/>
                <participants group_id="P2" count="290"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="230"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
                <participants group_id="P2" count="280"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="218"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Enrolled but Never Treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator's Discretion</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Analysis Set: participants who were enrolled and received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>SOF+PEG+RBV 12 Weeks (GT 1 and GT6)</title>
          <description>Participants with genotype 1 or 6 received SOF 400 mg tablet once daily + PEG 180 µg/0.5 mL pre-filled syringe administered subcutaneously once a week + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>SOF+RBV 12 Weeks (GT1 and GT6)</title>
          <description>Participants with genotype 1 or 6 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>SOF+RBV 16 Weeks (GT1 and GT6)</title>
          <description>Participants with genotype 1 or 6 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 16 weeks</description>
        </group>
        <group group_id="B4">
          <title>SOF+RBV 24 Weeks (GT1 and GT6)</title>
          <description>Participants with genotype 1 or 6 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 24 weeks</description>
        </group>
        <group group_id="B5">
          <title>SOF+RBV 12 Weeks (GT2)</title>
          <description>Participants with genotype 2 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks</description>
        </group>
        <group group_id="B6">
          <title>SOF+RBV 24 Weeks (GT3)</title>
          <description>Participants with genotype 3 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 24 weeks</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="155"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="104"/>
            <count group_id="B5" value="280"/>
            <count group_id="B6" value="126"/>
            <count group_id="B7" value="686"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" spread="12.8"/>
                    <measurement group_id="B2" value="43" spread="17.2"/>
                    <measurement group_id="B3" value="43" spread="17.6"/>
                    <measurement group_id="B4" value="49" spread="13.3"/>
                    <measurement group_id="B5" value="53" spread="12.3"/>
                    <measurement group_id="B6" value="40" spread="8.1"/>
                    <measurement group_id="B7" value="47" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="61"/>
                    <measurement group_id="B5" value="160"/>
                    <measurement group_id="B6" value="56"/>
                    <measurement group_id="B7" value="351"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="120"/>
                    <measurement group_id="B6" value="70"/>
                    <measurement group_id="B7" value="335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="104"/>
                    <measurement group_id="B5" value="280"/>
                    <measurement group_id="B6" value="126"/>
                    <measurement group_id="B7" value="686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="98"/>
                    <measurement group_id="B5" value="280"/>
                    <measurement group_id="B6" value="126"/>
                    <measurement group_id="B7" value="676"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Disclosed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="69"/>
                    <measurement group_id="B5" value="64"/>
                    <measurement group_id="B6" value="126"/>
                    <measurement group_id="B7" value="389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="129"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="87"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vietnam</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCV Genotype</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Genotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="81"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="280"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="126"/>
                    <measurement group_id="B7" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IL28b Status</title>
          <description>The CC, CT, and TT alleles are different forms of the IL28b gene.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>CC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="74"/>
                    <measurement group_id="B5" value="237"/>
                    <measurement group_id="B6" value="102"/>
                    <measurement group_id="B7" value="546"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="42"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCV RNA</title>
          <units>log10 IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.5" spread="0.74"/>
                    <measurement group_id="B2" value="6.3" spread="0.49"/>
                    <measurement group_id="B3" value="6.2" spread="0.88"/>
                    <measurement group_id="B4" value="6.5" spread="0.71"/>
                    <measurement group_id="B5" value="6.2" spread="0.96"/>
                    <measurement group_id="B6" value="6.2" spread="0.71"/>
                    <measurement group_id="B7" value="6.3" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCV RNA Category</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt; 800,000 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="87"/>
                    <measurement group_id="B6" value="32"/>
                    <measurement group_id="B7" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 800,000 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="82"/>
                    <measurement group_id="B5" value="193"/>
                    <measurement group_id="B6" value="94"/>
                    <measurement group_id="B7" value="516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)</title>
        <description>SVR12 is defined as HCV RNA &lt; the lower limit of quantification (LLOQ; ie, &lt; 25 IU/mL) 12 weeks following the last dose of study drug.</description>
        <time_frame>Posttreatment Week 12</time_frame>
        <population>Full Analysis Set: participants who enrolled in the study and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>SOF+PEG+RBV 12 Weeks (GT 1 and GT6)</title>
            <description>Participants with genotype 1 or 6 received SOF 400 mg tablet once daily + PEG 180 µg/0.5 mL pre-filled syringe administered subcutaneously once a week + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>SOF+RBV 12 Weeks (GT1 and GT6)</title>
            <description>Participants with genotype 1 or 6 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>SOF+RBV 16 Weeks (GT1 and GT6)</title>
            <description>Participants with genotype 1 or 6 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 16 weeks</description>
          </group>
          <group group_id="O4">
            <title>SOF+RBV 24 Weeks (GT1 and GT6)</title>
            <description>Participants with genotype 1 or 6 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 24 weeks</description>
          </group>
          <group group_id="O5">
            <title>SOF+RBV 12 Weeks (GT2)</title>
            <description>Participants with genotype 2 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks</description>
          </group>
          <group group_id="O6">
            <title>SOF+RBV 24 Weeks (GT3)</title>
            <description>Participants with genotype 3 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)</title>
          <description>SVR12 is defined as HCV RNA &lt; the lower limit of quantification (LLOQ; ie, &lt; 25 IU/mL) 12 weeks following the last dose of study drug.</description>
          <population>Full Analysis Set: participants who enrolled in the study and received at least one dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="104"/>
                <count group_id="O5" value="280"/>
                <count group_id="O6" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.5" lower_limit="90.9" upper_limit="98.2"/>
                    <measurement group_id="O2" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="71.5" upper_limit="100"/>
                    <measurement group_id="O4" value="94.2" lower_limit="87.9" upper_limit="97.9"/>
                    <measurement group_id="O5" value="96.8" lower_limit="94.0" upper_limit="98.5"/>
                    <measurement group_id="O6" value="95.2" lower_limit="89.9" upper_limit="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event</title>
        <time_frame>Up to 24 weeks</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>SOF+PEG+RBV 12 Weeks</title>
            <description>Participants with genotype (GT) 1 or 6 received SOF 400 mg tablet once daily + PEG 180 µg/0.5 mL pre-filled syringe administered subcutaneously once a week + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>SOF+RBV 12 Weeks</title>
            <description>Participants with genotype 1, 2 or 6 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>SOF+RBV 16 Weeks</title>
            <description>Participants with genotype 1 or 6 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>SOF+RBV 24 Weeks</title>
            <description>Participants with genotype 1, 3 or 6 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event</title>
          <population>Safety Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="290"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Sustained Virologic Response 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</title>
        <description>SVR4 and SVR24 are defined as HCV RNA &lt; LLOQ at 4 and 24 weeks following the last dose of study drug, respectively.</description>
        <time_frame>Posttreatment Weeks 4 and 24</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>SOF+PEG+RBV 12 Weeks (GT 1 and GT6)</title>
            <description>Participants with genotype 1 or 6 received SOF 400 mg tablet once daily + PEG 180 µg/0.5 mL pre-filled syringe administered subcutaneously once a week + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>SOF+RBV 12 Weeks (GT1 and GT6)</title>
            <description>Participants with genotype 1 or 6 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>SOF+RBV 16 Weeks (GT1 and GT6)</title>
            <description>Participants with genotype 1 or 6 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 16 weeks</description>
          </group>
          <group group_id="O4">
            <title>SOF+RBV 24 Weeks (GT1 and GT6)</title>
            <description>Participants with genotype 1 or 6 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 24 weeks</description>
          </group>
          <group group_id="O5">
            <title>SOF+RBV 12 Weeks (GT2)</title>
            <description>Participants with genotype 2 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks</description>
          </group>
          <group group_id="O6">
            <title>SOF+RBV 24 Weeks (GT3)</title>
            <description>Participants with genotype 3 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sustained Virologic Response 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</title>
          <description>SVR4 and SVR24 are defined as HCV RNA &lt; LLOQ at 4 and 24 weeks following the last dose of study drug, respectively.</description>
          <population>Full Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="104"/>
                <count group_id="O5" value="280"/>
                <count group_id="O6" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.8" lower_limit="92.6" upper_limit="98.9"/>
                    <measurement group_id="O2" value="100" lower_limit="69.2" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O4" value="94.2" lower_limit="87.9" upper_limit="97.9"/>
                    <measurement group_id="O5" value="97.5" lower_limit="94.9" upper_limit="99.0"/>
                    <measurement group_id="O6" value="97.6" lower_limit="93.2" upper_limit="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.5" lower_limit="90.9" upper_limit="98.2"/>
                    <measurement group_id="O2" value="100" lower_limit="69.2" upper_limit="100.0"/>
                    <measurement group_id="O3" value="90.9" lower_limit="58.7" upper_limit="99.8"/>
                    <measurement group_id="O4" value="94.2" lower_limit="87.9" upper_limit="97.9"/>
                    <measurement group_id="O5" value="96.8" lower_limit="94.0" upper_limit="98.5"/>
                    <measurement group_id="O6" value="95.2" lower_limit="89.9" upper_limit="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With On-Treatment Virologic Failure</title>
        <description>Viral breakthrough was defined as HCV RNA ≥ LLOQ after having previously had HCV RNA &lt; LLOQ while receiving treatment.</description>
        <time_frame>Up to 24 weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>SOF+PEG+RBV 12 Weeks (GT 1 and GT6)</title>
            <description>Participants with genotype 1 or 6 received SOF 400 mg tablet once daily + PEG 180 µg/0.5 mL pre-filled syringe administered subcutaneously once a week + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>SOF+RBV 12 Weeks (GT1 and GT6)</title>
            <description>Participants with genotype 1 or 6 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>SOF+RBV 16 Weeks (GT1 and GT6)</title>
            <description>Participants with genotype 1 or 6 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 16 weeks</description>
          </group>
          <group group_id="O4">
            <title>SOF+RBV 24 Weeks (GT1 and GT6)</title>
            <description>Participants with genotype 1 or 6 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 24 weeks</description>
          </group>
          <group group_id="O5">
            <title>SOF+RBV 12 Weeks (GT2)</title>
            <description>Participants with genotype 2 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks</description>
          </group>
          <group group_id="O6">
            <title>SOF+RBV 24 Weeks (GT3)</title>
            <description>Participants with genotype 3 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With On-Treatment Virologic Failure</title>
          <description>Viral breakthrough was defined as HCV RNA ≥ LLOQ after having previously had HCV RNA &lt; LLOQ while receiving treatment.</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="104"/>
                <count group_id="O5" value="280"/>
                <count group_id="O6" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Viral Relapse</title>
        <description>Viral relapse was defined as HCV RNA ≥ LLOQ during the post-treatment period having achieved HCV RNA &lt; LLOQ at end of treatment, confirmed with 2 consecutive values or last available post-treatment measurement.</description>
        <time_frame>Up to Posttreatment Week 24</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>SOF+PEG+RBV 12 Weeks (GT 1 and GT6)</title>
            <description>Participants with genotype 1 or 6 received SOF 400 mg tablet once daily + PEG 180 µg/0.5 mL pre-filled syringe administered subcutaneously once a week + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>SOF+RBV 12 Weeks (GT1 and GT6)</title>
            <description>Participants with genotype 1 or 6 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>SOF+RBV 16 Weeks (GT1 and GT6)</title>
            <description>Participants with genotype 1 or 6 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 16 weeks</description>
          </group>
          <group group_id="O4">
            <title>SOF+RBV 24 Weeks (GT1 and GT6)</title>
            <description>Participants with genotype 1 or 6 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 24 weeks</description>
          </group>
          <group group_id="O5">
            <title>SOF+RBV 12 Weeks (GT2)</title>
            <description>Participants with genotype 2 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks</description>
          </group>
          <group group_id="O6">
            <title>SOF+RBV 24 Weeks (GT3)</title>
            <description>Participants with genotype 3 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Viral Relapse</title>
          <description>Viral relapse was defined as HCV RNA ≥ LLOQ during the post-treatment period having achieved HCV RNA &lt; LLOQ at end of treatment, confirmed with 2 consecutive values or last available post-treatment measurement.</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="104"/>
                <count group_id="O5" value="280"/>
                <count group_id="O6" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HCV RNA (log10 IU/mL)</title>
        <time_frame>Up to 24 weeks</time_frame>
        <population>Participants in the Full Analysis Set with available data were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>SOF+PEG+RBV 12 Weeks (GT 1 and GT6)</title>
            <description>Participants with genotype 1 or 6 received SOF 400 mg tablet once daily + PEG 180 µg/0.5 mL pre-filled syringe administered subcutaneously once a week + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>SOF+RBV 12 Weeks (GT1 and GT6)</title>
            <description>Participants with genotype 1 or 6 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>SOF+RBV 16 Weeks (GT1 and GT6)</title>
            <description>Participants with genotype 1 or 6 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 16 weeks</description>
          </group>
          <group group_id="O4">
            <title>SOF+RBV 24 Weeks (GT1 and GT6)</title>
            <description>Participants with genotype 1 or 6 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 24 weeks</description>
          </group>
          <group group_id="O5">
            <title>SOF+RBV 12 Weeks (GT2)</title>
            <description>Participants with genotype 2 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks</description>
          </group>
          <group group_id="O6">
            <title>SOF+RBV 24 Weeks (GT3)</title>
            <description>Participants with genotype 3 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HCV RNA (log10 IU/mL)</title>
          <population>Participants in the Full Analysis Set with available data were analyzed</population>
          <units>log10 IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="104"/>
                <count group_id="O5" value="280"/>
                <count group_id="O6" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="104"/>
                    <count group_id="O5" value="278"/>
                    <count group_id="O6" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.81" spread="0.653"/>
                    <measurement group_id="O2" value="-4.59" spread="0.359"/>
                    <measurement group_id="O3" value="-4.36" spread="0.560"/>
                    <measurement group_id="O4" value="-4.61" spread="0.607"/>
                    <measurement group_id="O5" value="-4.46" spread="0.815"/>
                    <measurement group_id="O6" value="-4.52" spread="0.695"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="154"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="280"/>
                    <count group_id="O6" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.11" spread="0.734"/>
                    <measurement group_id="O2" value="-4.89" spread="0.488"/>
                    <measurement group_id="O3" value="-4.79" spread="0.858"/>
                    <measurement group_id="O4" value="-5.04" spread="0.682"/>
                    <measurement group_id="O5" value="-4.78" spread="1.008"/>
                    <measurement group_id="O6" value="-4.86" spread="0.706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="104"/>
                    <count group_id="O5" value="280"/>
                    <count group_id="O6" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.12" spread="0.738"/>
                    <measurement group_id="O2" value="-4.89" spread="0.488"/>
                    <measurement group_id="O3" value="-4.82" spread="0.880"/>
                    <measurement group_id="O4" value="-5.12" spread="0.710"/>
                    <measurement group_id="O5" value="-4.81" spread="1.025"/>
                    <measurement group_id="O6" value="-4.87" spread="0.713"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="104"/>
                    <count group_id="O5" value="280"/>
                    <count group_id="O6" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.12" spread="0.738"/>
                    <measurement group_id="O2" value="-4.89" spread="0.488"/>
                    <measurement group_id="O3" value="-4.82" spread="0.880"/>
                    <measurement group_id="O4" value="-5.12" spread="0.710"/>
                    <measurement group_id="O5" value="-4.80" spread="1.038"/>
                    <measurement group_id="O6" value="-4.87" spread="0.713"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="279"/>
                    <count group_id="O6" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.12" spread="0.738"/>
                    <measurement group_id="O2" value="-4.89" spread="0.488"/>
                    <measurement group_id="O3" value="-4.82" spread="0.880"/>
                    <measurement group_id="O4" value="-5.12" spread="0.708"/>
                    <measurement group_id="O5" value="-4.83" spread="0.966"/>
                    <measurement group_id="O6" value="-4.87" spread="0.713"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="279"/>
                    <count group_id="O6" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.12" spread="0.738"/>
                    <measurement group_id="O2" value="-4.89" spread="0.488"/>
                    <measurement group_id="O3" value="-4.82" spread="0.880"/>
                    <measurement group_id="O4" value="-5.12" spread="0.708"/>
                    <measurement group_id="O5" value="-4.83" spread="0.966"/>
                    <measurement group_id="O6" value="-4.87" spread="0.713"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="154"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="278"/>
                    <count group_id="O6" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.12" spread="0.739"/>
                    <measurement group_id="O2" value="-4.89" spread="0.488"/>
                    <measurement group_id="O3" value="-4.82" spread="0.880"/>
                    <measurement group_id="O4" value="-5.12" spread="0.708"/>
                    <measurement group_id="O5" value="-4.83" spread="0.966"/>
                    <measurement group_id="O6" value="-4.84" spread="0.779"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-4.82" spread="0.880"/>
                    <measurement group_id="O4" value="-5.12" spread="0.708"/>
                    <measurement group_id="O6" value="-4.87" spread="0.713"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="102"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="-5.14" spread="0.701"/>
                    <measurement group_id="O6" value="-4.87" spread="0.713"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="102"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="-5.14" spread="0.701"/>
                    <measurement group_id="O6" value="-4.87" spread="0.713"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 24 Weeks Plus 30 Days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SOF+PEG+RBV 12 Weeks</title>
          <description>Participants with genotype 1 or 6 received SOF 400 mg tablet once daily + PEG 180 µg/0.5 mL pre-filled syringe administered subcutaneously once a week + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>SOF+RBV 12 Weeks</title>
          <description>Participants with genotype 1, 2 or 6 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>SOF+RBV 16 Weeks</title>
          <description>Participants with genotype 1 or 6 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks</description>
        </group>
        <group group_id="E4">
          <title>SOF+RBV 24 Weeks</title>
          <description>Participants with genotype 1, 3 or 6 received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 24 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Angle closure glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Hepatic lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Fibroadenoma of breast</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="145" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="215" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="177" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Red blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Reticulocyte count increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:
The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or
The study has been completed at all study sites for at least 2 years</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosures</name_or_title>
      <organization>Gilead Sciences</organization>
      <email>ClinicalTrialDisclosures@gilead.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

